A case of Alström syndrome with growth hormone deficiency and dyslipidemia: a novel homozygous frameshift variant of ALMS1 c.5763del
Journal of Pediatric Endocrinology and Metabolism · 24.07.2026 · 39 (7) · 727-732
DOI: 10.1515/jpem-2025-0735 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 07.04.2026. Verfasst von Takeshi Goda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, 12898 Kyoto Prefectural University of Medicine , Kyoto, Japan. Hauptthemen laut MEDLINE: Alstrom Syndrome, Dyslipidemias, Frameshift Mutation, Human Growth Hormone. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objectives
Alström syndrome (AS, OMIM #203800) is a rare autosomal recessive disorder caused by biallelic pathogenic variants in ALMS1 , characterized by obesity, cardiomyopathy, retinal dystrophy, sensorineural hearing loss, and progressive hepatic and renal involvement. We report a pediatric case of AS complicated by growth hormone deficiency (GHD), focusing on the clinical course and potential metabolic effects of growth hormone (GH) replacement therapy. Case presentation A 13-year-old girl with AS presented with severe dyslipidemia, including hypertriglyceridemia (727 mg/dL), elevated total cholesterol (251 mg/dL), and low high-density lipoprotein cholesterol (23 mg/dL), together with dilated cardiomyopathy. She was diagnosed with GHD at 3 years of age, with a height of −3.6 SD. GH replacement therapy led to sustained improvement in linear growth, reaching −1.9 SD, and was associated with long-term maintenance of lipid parameters within the normal range. Whole-exome sequencing identified a previously unreported homozygous frameshift variant in ALMS1 (NM_001378454.1:c.5763del; p.(Phe1921Leufs*18)).
Conclusions
This case suggests that GH replacement therapy may contribute to improved lipid metabolism in patients with AS complicated by GHD. In addition, it expands the mutational spectrum of ALMS1 and highlights the potential metabolic benefits of early endocrine intervention in AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, 12898 Kyoto Prefectural University of Medicine , Kyoto, Japan.
ORCID-Profile: Hisakazu Nakajima
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Goda, T., Nakajima, H., Kawabe, Y., Kosaka, K., Itoi, T., Kawai, Y., Sugimoto, S., & Iehara, T. (2026). A case of Alström syndrome with growth hormone deficiency and dyslipidemia: a novel homozygous frameshift variant of ALMS1 c.5763del. Journal of Pediatric Endocrinology and Metabolism, 39(7), 727-732. https://doi.org/10.1515/jpem-2025-0735
Vancouver
Goda T, Nakajima H, Kawabe Y, Kosaka K, Itoi T, Kawai Y, et al. A case of Alström syndrome with growth hormone deficiency and dyslipidemia: a novel homozygous frameshift variant of ALMS1 c.5763del. Journal of Pediatric Endocrinology and Metabolism. 2026;39(7):727-732. doi:10.1515/jpem-2025-0735
BibTeX
@article{Goda2026,
author = {Goda, Takeshi and Nakajima, Hisakazu and Kawabe, Yasuhiro and Kosaka, Kitaro and Itoi, Toshiyuki and Kawai, Yoko and Sugimoto, Satoru and Iehara, Tomoko},
title = {A case of Alström syndrome with growth hormone deficiency and dyslipidemia: a novel homozygous frameshift variant of ALMS1 c.5763del},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2026},
volume = {39},
number = {7},
pages = {727--732},
doi = {10.1515/jpem-2025-0735}
}
EUVIMED